Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Gubra A/S Director's Dealing 2026

Jun 4, 2026

6302_rns_2026-06-04_b7ef6b87-d13c-4ad3-ba1d-adca08bfd5e9.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Regulatory press release

04 June 2026 10:19:00 CEST

gubra

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name Markus Rohrwild
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/ Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Gubra A/S
b) LEI 254900T17RRFZONO6W53
4.1 Details of the transaction(s):
a) Description of the financial instrument, type of instrument Warrants related to the shares of Gubra A/S
Identification code Shares (ISIN DK0062266474)
b) Nature of the transaction Warrants granted free of charge in connection with the Company's incentive programme.

Gubra

Hørsholm Kongevej 11B

2970 Hørsholm


Regulatory press release

04 June 2026 10:19:00 CEST

gubra

c) Price(s) and volume(s) Price(s) Volume(s)
DKK 0 31,147
d) Aggregated information
— Aggregated volume
— Price Average price per share: DKK 0
Total number of warrants: 31,147
Total price: DKK 0
e) Date of the transaction 2 June 2026
f) Place of the transaction Outside a trading venue

Contacts at Gubra

Media: Marianne Thomas ([email protected], +45 2483 2663)

Investors: Kristian Borbos ([email protected], +45 3080 8035) and Adam Lange ([email protected], +45 +45 6646 1589)

About Gubra

Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra's activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.

Gubra

Hørsholm Kongevej 11B

2970 Hørsholm